- Home
- RYTM vs CHDN Comparison
RYTM vs CHDN Comparison
Compare RYTM & CHDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYTM | CHDN |
|---|---|---|
| Founded | 2008 | 1928 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.0B |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RYTM | CHDN |
|---|---|---|
| Price | $105.64 | $84.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | $131.14 | ★ $138.44 |
| AVG Volume (30 Days) | 872.9K | ★ 994.9K |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.43% |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ 5.49 |
| Revenue | N/A | ★ $1,809,800,000.00 |
| Revenue This Year | $55.34 | $5.75 |
| Revenue Next Year | $86.06 | $3.52 |
| P/E Ratio | ★ N/A | $15.70 |
| Revenue Growth | N/A | ★ 13.31 |
| 52 Week Low | $74.50 | $81.45 |
| 52 Week High | $122.20 | $118.46 |
Technical Indicators
Market Signals| Indicator | RYTM | CHDN |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 42.93 |
| Support Level | $98.30 | N/A |
| Resistance Level | $113.51 | $90.25 |
| Average True Range (ATR) | 4.38 | 2.95 |
| MACD | -1.22 | -0.30 |
| Stochastic Oscillator | 21.67 | 13.67 |
Price Performance
Historical ComparisonAbout RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
About CHDN Churchill Downs Incorporated
Churchill Downs Inc is a gaming entertainment, online wagering, and racing company. It operates through three business segments: Live and Historical Racing, Wagering Services, and Gaming. The Live and Historical Racing segment includes live and historical pari-mutuel racing. The Wagering Services segment includes the revenue and expenses from pari-mutuel wagers through TwinSpires, companies retail and online sports betting business and Gaming segment includes revenue and expenses for the casino properties and associated racetracks that support the casino license. The Gaming segment generates revenue and expenses from slot machines, video lottery terminals, video poker, HRMs, ancillary food and beverage services, hotel services, commission on pari-mutuel wagering, and racing events.